Background: Apolipoprotein B (ApoB) levels have been shown to be associate with risk of ischemic stroke. The apolipoprotein B gene (APOB) polymorphisms may influence levels of ApoB and risk of ischemic stroke, but whether they are associated with risk of ischemic cerebral infarction (CI) with family history (CIFH) or not is unknown. Aims: To investigate the possible association of the polymorphism of APOB C7673T with CIFH in Han Chinese from Changsha. Settings and Design: The study population included 47 patients with CIFH and 83 patients with cerebral infarction with no family histroy (CINFH). Control population included 100 healthy subjects with no history of ischemic stroke matched for age, sex, and ethnic background. Materials and Methods: The APOB C7673T polymorphism was analyzed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Plasma lipids levels were also examined by standard enzymatic methods and enzyme-linked immunosorbent assay (ELISA). Statistics: The statistical analysis was done using SPSS 14.0 software package. A P value , 0.05 was taken as significant. Results: This study showed an association between the APOB C7673T polymorphism and CI, especially CIFH in Han Chinese from Changsha. The T alleles frequency of the C7673T polymorphism was significantly higher in both the CIFH and CINFH groups when compared with the control group (P , 0.01; P , 0.05; respectively). And the T allele frequency in CIFH group (0.17) was higher than CINFH (0.09) group (P 5 0.056). In both the CIFH and CINFH groups the serum levels of TC and LDL cholesterol were significantly high in the TT and TC genotypes than that in the CC genotype (P , 0.01), while the serum level of HDL cholesterol in the TT and TC genotypes was significantly lower than that in the CC genotype (P , 0.05). Conclusions: The APOB C7673T polymorphism is related to CI, especially CIFH through changing serum lipid levels in a Chinese population.
Introduction
Ischemic stroke (IS) is the leading cause of mortality and disability in China, and in about 78% of ISs the mechanism is atherothrombotic. [1] There is significant familial aggregation in the occurrence of atherothrombotic IS. [2] The aetiology of IS is heterogeneous and the recent studies emphasises the contribution of genetic as well as environmental factors. [3] Although no gene has been convincingly shown to be of importance for cerebral ischemia (CI), the obvious candidate genes are those with an established or potential role in atherosclerosis. [4] Apolipoprotein B (ApoB) plays a central role in lipid transport throughout the body. In addition to its lipid-transport function, ApoB is the major atherogenic apolipoprotein in humans and experimental animals. [5] The gene coding for ApoB is polymorphic, and it has been reported this genetically determined variation has a close relationship with the pathogenesis of atherosclerosis. [6] Although apolipoprotein B (APOB) C7673T polymorphism is not involved in amino acid change, it was reported to play an important role in the pathogenesis of atherosclerosis coronary heart disease and myocardial infarction. [7] Our previous study has indicated that APOB C7673T polymorphism is associated with cerebral hemorrhage in Changsha Han Chinese. [8] In this study we, investigated the importance of APOB C7673T polymorphism as a risk factor for cerebral infarction with family history (CIFH) and also its relationship with serum lipid levels in the Chinese population.
Materials and Methods
This was a case-control study conducted in the Department of Neurology, Xiangya Hospital, Changsha, Hunan, People's Republic of China from January 2005 to October 2008. All subjects enrolled in the study were Han Chinese. The diagnosis of CI was established by clinical evaluation and brain magnetic resonance imaging (MRI). The diagnostic criteria were based on the World Health Organization International Classification  of Diseases, 9 th Revision, codes 430-438. Patients with CIFH were defined as patients with at least one first degree relative with IS. The study population consisted of 47 patients with CIFH (25 males and 22 females; mean age, 53.48 6 10.22 years) and 83 patients with cerebral infarction without family history (CINFH) (45 males and 38 females; mean age, 58.62 6 10.37 years). The contols included 100 healthy subjects with no history of CI matched for age, sex and ethenic group (53 males and 47 females; mean age, 53.82 6 13.26 years) and were randomly recurited from healthy individual of the hospital. The healthy controls were genotyped in our previous study. [8] Patients with cardioembolic CI and CI due to arteritis, trauma, hemotological diseases, and drugs were excluded. Other patients excluded from the study included patients with liver disease, renal disease, autoimmune diseases, pregnant women and also patients on lipid-lowering therapy within the previous five years.
Detailed information on vascular risk factors: Sex, age, body mass index (BMI), hypertension, diabetes mellitus, ischemic heart disease, smoking history (defines as current, past, or never), and medication use (particularly antihypertensive drug and lipid-lowering agents) was obtained from each subject at baseline. BMI was calculated by the formula, weight divided by square root of the height (kg/m 2 ) and hypertension was defined as blood pressure $ 140/90 mmHg measured on two separate occasions and/or the use of antihypertensive medication. All the subjects had their fasting serum total cholesterol (TC), triglyceride (TG), and high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), ApoAI, ApoB100 and lipoprotein(a) on the day of the event. Serum levels of TC, HDL, and TG were measured by standard enzymatic methods. LDL cholesterol levels were calculated with the Friedewald formula (LDL 5 TC-HDL-C-TG/5). If both, total cholesterol and triglyceride levels, are elevated then a modified formula was used: LDL-C 5 TC-HDL-C-(0.16 3 TG), which provided an approximation with fair accuracy for most people. LP (a) levels were measured by ELISA. The levels of ApoB100 and ApoAI were detected by immunoturbidimetric assay.
Genomic DNA was extracted from peripheral blood leukocytes in all the patients and controls using proteinase K and the phenol/chloroform method. The determination of APOB C7673T polymorphism was done by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). [9] The amplification reaction was carried out using primers: 59-GGAGACTATTCAGAAGCTAA-39 and 59-GAAGAGCCTGAAGACTGACT-39 and the following cycling conditions. Each amplification reaction was performed with 100 ng of genomic DNA; 10 pmol of each primer; 2 mL of 10 3 buffer solution; 200 mmol/L each of dATP, dCTP, dGTP, and dTTP; and 1 U of Taq polymerase in a total volume of 20 mL. The DNA fragments were generated from initial denaturation at 95°C for 2.5 minutes, followed by 30 cycles of denaturation at 94°C for 30 seconds, annealing at 58°C for 40 seconds, and extension at 72°C for 60 seconds, with final extension at 72°C for 5 minutes. The amplification products were digested with the restriction enzyme XbaI, and the fragments were separated on a 4% agarose gel. Five randomly chosen samples with positive genotyping results were confirmed further by direct sequencing of the PCR products with an automated DNA sequencer.
Statistical analyses were performed using SPSS 14.0. The mean levels of TC, TG, LDL, and HDL in different groups were compared using Student's t-test. Frequencies of the genotypes and alleles were analyzed using Zhang, et al.: Apolipoprotein B gene polymorphism in cerebral infarction the x 2 test. The odds ratio (OR) and 95% confidential intervel (CI) were calculated to measure the strength of the association. Statistical significance was defined as P , 0.05.
Results

Clinical characteristics
The characteristics of study subjects, patients and controls are summarized in Table 1 . The two groups were well matched for age and sex. There were no significant differences in BMI, smoking history or history of ischemic heart diseases. The difference in history of hypertension, history of diabetes and family history of CI was significant.
Allele frequencies of apolipoprotein B gene C7673T polymorphism and genotypes
Results of the C7673T polymorphism are shown in Figure 1 and the genotype distribution and the allele frequency for APOB C7673T polymorphism in Table 2 . Genotype frequencies did not significantly deviate from Hardy-Weinberg equilibrium in patients with CI and in controls (P . 0.05). As shown in Table 2 , there were only two genotypes (TC and CC) in CIFH and CINFH groups, while there were three genotypes (TC, CC, and TT) in the control group. The T alleles frequency of the C7673T polymorphism was significantly higher in CIFH and CINFH groups when compared with the control group (P , 0.01; P , 0.05; respectively). And the T allele frequency in CIFH group (0.17) was higher than CINFH (0.09) group (P 5 0.056), but with no statistical significant difference.
Effect on lipid profile
The relation between the C7673T polymorphism and the serum lipids in CIFH, CINFH and the control groups are shown in Table 3 . In both the CIFH and CINFH groups the serum levels of TC and LDL cholesterol were significantly high in the TT and TC genotypes than that in the CC genotype (P , 0.01), while the serum level of HDL cholesterol in the TT and TC genotypes *P , 0.01 for the comparison between patients and controls: # P , 0.05 for the comparison between patients and controls but more significant difference could be seen in TC, TG, HDL-C, and LDL-C between the two groups; CI: Cerebral infarction For the comparison with the CC genotype, P , 0.05; CIFH -Cerebral infarction with family history; CINFH -Cerebral infarction with no family history was significantly lower than that in the CC genotype (P , 0.05). There were no significant differences in the serum levels of TG, ApoAI, ApoB100 and Lp(a) (P . 0.05) among the subgroups in the CIFH, CINFH, and controls groups.
Discussion
Cerebral infarction is a disease with familial clustering [10, 11] and is associated with ApoB. [12] The gene coding for ApoB is polymorphic and has a close relationship with the pathogenesis of atherosclerosis; [13] however, little is known about the role of the APOB polymorphism in patients with CIFH. In our study, the T allele frequency was significantly higher in patients with CIFH and CINFH than in control subjects (P , 0.01, P , 0.05, respectively). Further, the T allele frequency in the CIFH group (0.17) was higher than in the CINFH (0.09) group. These results suggest the T allele of APOB C7637T polymorphism was not only associated with cerebral infarction, but also with CIFH in Han Chinese from Changsha. In our earlier study we have shown an association of T allele of APOB C7673T in cerebral hemorrhage. [8] The results from these two studies show further evidence for the association between atherosclerosis and APOB.
The APOB is located on chromosome 2q23, spanning approximately 43 kb and has 29 exons and 28 introns. [14] Polymorphisms in APOB may be associated with increased or decreased levels of APOB and LDL cholesterol. [15, 16] The C7673T polymorphism has been located just adjacent to the area of the LDL receptor. This polymorphism is a consequence of a C to T transversion at nucleotide 7673 in exon 26, which converts the 2488 codon ACC to ACT. The C7673T mutation creates an XbaI recognition site, that is called allele T (X 1), digestion of the PCR product of the mutant allele by this enzyme generates 2 fragments (433 and 277 bp). Though polymorphism of APOB C7673T does not lead to direct amino acid change, it still may play an important role in the pathogenesis of atherosclerosis and is related to coronary heart disease and myocardial infarction. [7] All this suggests that the C7673T polymorphism of ApoB should have a potential effect on the pathogenesis of CI. Our study suggests that the T allele of APOB C7637T polymorphism is associated with CI and CIFH in Han Chinese from Changsha.
Our study found the serum TC and LDL cholesterol levels in patients with TC or TT genotypes were significantly higher while the HDL cholesterol was significantly lower than those in CC genotype. Some of the earlier studies have shown that the APOB C7673T polymorphism was associated with the serum levels of TC, LDL cholesterol and ApoB, and played an important role in the pathogenesis of atherosclerosis. [12, 17] Saha [17] demonstrated significantly low levels of serum HDL cholesterol in TC genotype than in the CC genotype, and the T allele of APOB C7673T polymorphism was negatively associated with the serum HDL cholesterol level. They also found that the median serum TC level in TT genotype was 11,14% higher than that in CC genotype of the C7673T polymorphism, and the median serum LDL cholesterol level in TT genotype was 21% higher than that in CC genotype. [17] Our findings were similar to the observations in the earlier studies, [17, 18] and have further established the association between the APOB C7673T polymorphism serum lipid metabolism in Han Chinese from Changsha.
The in vivo catabolism of serum lipoprotein is by its interaction with the lipoprotein receptor. Lipoprotein receptor is the protein located on the cell membrane and has a high affinity for the serum lipoprotein and the receptors are located on all the cell membranes, particularly on the hepatic cells and involved in the catabolism of LDL, intermediate-density lipoprotein (IDL) and very low-density lipoprotein (VLDL) cholesterol. [19] Renges et al., [20] showed that APOB polymorphism was an important genetic marker, and exhibit transmission disequilibrium with other nearby DNA sequence mutations which could also affect serum lipid metabolism. Those DNA sequence mutations may occur in the ApoB receptor combination area, leading to ApoB protein structure changes and thus decreasing the ability of LDL cholesterol to bind to the receptor. This can affect the catabolism of LDL cholesterol and lead to increased serum lipid levels in vivo. [20] So we suppose APOB C7673T polymorphism correlates with CI, especially CIFH. It may be an internal susceptibility factor of serum lipid level increasing, and by changing the metabolism of serum lipid in vivo indirectly, APOB C7673T polymorphism takes part in the progression of atherosclerosis, and consequently takes part in the onset and progression of CI, especially of CIFH. Validation of our findings will require additional studies with more subjects.
